This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Best-Performing Liquid Stocks for Alluring Returns
by Radhika Pujara
Here are four excellent liquid stocks, including Logitech (LOGI), that can contribute to making an outstanding portfolio for investors.
Coty (COTY) Down on Wider-Than-Expected Q4 Loss & Drab Sales
by Zacks Equity Research
Coty's (COTY) fourth-quarter fiscal 2020 results reflect adverse impacts of coronavirus-led retail and salon closures. The company expects to return to profits in the first quarter of fiscal 2021.
6 Stocks Near 52-Week Highs That Can Carry The Momentum Further
by Anirudha Bhagat
Investors will target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum forward.
NUS vs. HELE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. HELE: Which Stock Is the Better Value Option?
Inter Parfums (IPAR) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Inter Parfums (IPAR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Altria Gains From Oral Products Amid Lower Cigarette Sales
by Zacks Equity Research
Despite dismal cigarette sales, pricing power and growth in oral tobacco are offering Altria (MO) some respite.
Estee Lauder's (EL) Q4 Loss Wider Than Estimates, Sales Down
by Zacks Equity Research
Estee Lauder's (EL) fourth-quarter fiscal 2020 sales decline due to coronavirus-induced retail store closures. The company launches a two-year plan called Post-COVID Business Acceleration Program.
Nu Skin, AZZ, Regal Beloit and Rexnord highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nu Skin, AZZ, Regal Beloit and Rexnord highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Nu Skin (NUS)
by David Bartosiak
A big jump in earnings estimates means this stock deserves a new look.
Has Nu Skin Enterprises (NUS) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (NUS) Outperforming Other Consumer Staples Stocks This Year?
Philip Morris Extends Deal With KT&G, RRPs Expansion on Track
by Zacks Equity Research
Philip Morris (PM) will start commercialization of KT&G's smoke-free alternatives outside South Korea, beginning with Russia.
Zacks.com featured highlights include: Medifast, ANGI Homeservices, Expeditors International of Washington and Nu Skin
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, ANGI Homeservices, Expeditors International of Washington and Nu Skin
Philip Morris Gains on RRPs & Pricing Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris' (PM) cigarette sales have been dismal due to lower demand and pandemic-led restrictions. Nevertheless, RRPs are depicting continued rise.
4 Top-Ranked Liquid Bets to Build a Successful Portfolio
by Radhika Pujara
Here are four top-ranked liquid stocks, including Medifast (MED) that investors can add to their portfolio for fat returns.
Cleaning Product Demand Aids P&G's Growth: Will it Persist?
by Zacks Equity Research
Procter & Gamble (PG) is one of the beneficiaries of the recent spike in demand for cleaning and disinfecting products amid the pandemic. However, currency headwinds continue to play spoilsport.
Inter Parfums (IPAR) Posts Narrower-Than-Expected Q2 Loss
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2020 results reflect lower sales thanks to coronavirus-induced retail outlet closures. Also, sales declined across all regions and brands.
6 Stocks Trading Near 52-Week Highs That Can Rally Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum forward.
Are Investors Undervaluing Nu Skin Enterprises (NUS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NUS vs. EL: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Nu Skin's (NUS) Q2 Earnings Beat Estimates, Sales Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2020 results reflect lower earnings and sales. Nevertheless, management raises 2020 view on better than expected year-to-date performance.
Nu Skin Enterprises (NUS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 20.90% and 1.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Flowers Foods (FLO) in Q2 Earnings?
by Zacks Equity Research
Strength in branded retail with Nature's Own, Canyon Bakehouse, Dave's Killer Bread and Wonder brands might reflect on Flowers Foods' (FLO) Q2 results.
Here's How Post Holdings (POST) Looks Ahead of Q3 Earnings
by Zacks Equity Research
Impacts of higher costs as well as lower demand in foodservice business are likely to get reflected in Post Holdings' (POST) third-quarter fiscal 2020 performance.
What's in the Cards for Medifast (MED) This Earnings Season?
by Zacks Equity Research
Strength in OPTAVIA brand is likely to get reflected in Medifast's (MED) second-quarter 2020 performance. However, rising SG&A expenses is a concern.
Clorox (CLX) Beats Q4 Earnings & Sales Estimates, Stock Down
by Zacks Equity Research
Clorox's (CLX) fourth-quarter fiscal 2020 results reflect gains from the robust demand for disinfecting and cleaning products due to the coronavirus outbreak, and broad-based growth at all segments.